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AE

:   adverse event

ALT

:   alanine aminotransferase

AST

:   aspartate aminotransferase

DLT

:   dose‐limiting toxicity

ECOG

:   Eastern Cooperative Oncology Group

ELISA

:   enzyme‐linked immunosorbent assay

FGF

:   fibroblast growth factor

FGFR

:   fibroblast growth factor receptor

FISH

:   fluorescence in situ hybridization

IS

:   internal standard

LC‐MS/MS

:   liquid chromatography‐tandem mass spectrometry

MTD

:   maximum tolerated dose

mTPI

:   modified toxicity probability interval

PD

:   pharmacodynamics

PK

:   pharmacokinetic

PPE

:   palmar‐plantar erythrodysesthesia

QD

:   once daily

RIA

:   radioimmunoassay

SAE

:   serious adverse event

TEAE

:   treatment‐emergent adverse event

1. INTRODUCTION {#cas14265-sec-0001}
===============

Fibroblast growth factor receptors are a family of four highly conserved transmembrane receptor tyrosine kinases (FGFR1‐4) that can bind FGF ligands.[1](#cas14265-bib-0001){ref-type="ref"} FGF signaling is implicated in downstream transduction pathways that regulate several key cellular processes, including proliferation, differentiation, migration, and survival.[2](#cas14265-bib-0002){ref-type="ref"} The signaling pathway is frequently perturbed in cancer, often manifesting as *FGFR* amplification and mutation, oncogenic fusion, dysregulated FGF ligand signaling, and promotion of angiogenesis.[3](#cas14265-bib-0003){ref-type="ref"} Although anti‐FGFR therapy represents a promising targeted cancer treatment, early phase clinical trials have had mixed success, with response to therapy dependent on several factors, including cancer type, tumor histology, and presence or absence of certain biomarkers.[4](#cas14265-bib-0004){ref-type="ref"}

Trials of non‐selective, multi‐target tyrosine kinase inhibitors have shown variable anti‐FGFR activity and broad‐spectrum off‐target inhibition of other tyrosine kinases, notably vascular endothelial growth factor, leading to toxicities.[5](#cas14265-bib-0005){ref-type="ref"} Off‐target inhibition has also been associated with several other AE, such as bone marrow suppression caused by platelet‐derived growth factor inhibition and skin rash caused by *KIT* inhibition.[6](#cas14265-bib-0006){ref-type="ref"} Thus, selective inhibitors may offer the benefit of reduced toxicity by eliminating concerns about such off‐target effects.

To date, several selective FGFR inhibitors have been assessed in early phase clinical testing. A phase I study of the selective FGFR1‐3 inhibitor AZD4547 in patients with squamous cell lung cancers confirmed target inhibition but failed to achieve its efficacy endpoint.[7](#cas14265-bib-0007){ref-type="ref"} In Japanese patients with advanced solid tumors, AZD4547 was well tolerated, with best response being stable disease (duration ≥4 weeks).[8](#cas14265-bib-0008){ref-type="ref"} BGJ398, another selective FGFR1‐3 inhibitor, showed antitumor activity in several tumor types and had a tolerable safety profile in a phase I study in patients with advanced solid tumors,[9](#cas14265-bib-0009){ref-type="ref"} whereas JNJ‐42756493, a pan‐FGFR inhibitor recently approved by the FDA for urothelial carcinoma,[10](#cas14265-bib-0010){ref-type="ref"} showed a clinical response with acceptable safety in a similar patient population.[11](#cas14265-bib-0011){ref-type="ref"} Similar findings have been reported for the pan‐FGFR inhibitors LY2874455[12](#cas14265-bib-0012){ref-type="ref"} and ARQ 087.[13](#cas14265-bib-0013){ref-type="ref"} Clinical trials are ongoing for other highly selective FGFR inhibitors in development, such as TAS‐120[14](#cas14265-bib-0014){ref-type="ref"} and INCB054828,[15](#cas14265-bib-0015){ref-type="ref"} in which patients are screened for FGFR abnormalities using next‐generation sequencing or FISH techniques.

E7090 is an orally available and potent selective inhibitor of the tyrosine kinase activities of FGFR1, ‐2, and ‐3, developed at the Eisai Tsukuba Research Laboratories. Based on its unique binding kinetics with FGFR1, E7090 is classified as a type V kinase inhibitor; in contrast, the developmental agent AZD4547 is a common type I inhibitor.[16](#cas14265-bib-0016){ref-type="ref"} In a human gastric cancer cell line (SNU‐16) that expresses high levels of FGFR2 protein, E7090 inhibited phosphorylation of both FGFR (IC~50~ = 1.2 nmol/L) and downstream molecules including FRS2α, ERK1/2, and AKT in a dose‐dependent method.[16](#cas14265-bib-0016){ref-type="ref"} E7090 also showed antitumor activity in preclinical models (in vitro assays and mouse xenografts using gastric, lung, bladder, or breast cancer cells) harboring FGFR genetic alterations such as FGFR1 and/or FGFR2 amplification, FGFR1 fusion, FGFR2 mutation, FGFR3 fusion, and FGFR3 mutation.[16](#cas14265-bib-0016){ref-type="ref"}

The aim of this first‐in‐human phase I study of E7090 was to evaluate the primary endpoints of safety and tolerability in patients with advanced solid tumors. Secondary endpoints included determination of the MTD of E7090 to identify the dose for future studies, and to establish its PK characteristics and preliminary antitumor activity. Exploratory objectives included identification of PD markers (including markers of FGFR pathway inhibition such as serum phosphate, FGF23, and 1,25‐(OH)~2~‐vitamin D)[17](#cas14265-bib-0017){ref-type="ref"} and pharmacogenomics of E7090; assessment of the relationships among PK variables, PD markers, and pharmacogenomics; and analysis of the plasma and urinary metabolites of E7090.

2. MATERIALS AND METHODS {#cas14265-sec-0002}
========================

2.1. Patients {#cas14265-sec-0003}
-------------

Patients aged ≥20 years with histologically or cytologically confirmed advanced solid tumors refractory to standard therapy, or for whom no appropriate treatment was available, were eligible for the study. Other inclusion criteria included corrected serum calcium and phosphate ≤ upper limit of normal and ECOG performance status of 0 or 1. Patients with brain metastasis associated with clinical symptoms or requiring treatment, current evidence or history of ≥ grade 2 corneal disorder, or a history of clinically significant cardiovascular impairment were excluded. Patients who had previously been treated with FGFR inhibitors were also excluded.

2.2. Study design {#cas14265-sec-0004}
-----------------

This first‐in‐human phase I study conducted in Japan consisted of two parts: a single‐center dose‐escalation study to assess DLT and to determine MTD in patients with advanced solid tumors (Part 1), and a multicenter expansion part restricted to patients with tumors harboring FGFR alterations, including gastric cancer with FGFR2 amplification and cholangiocarcinoma with FGFR2 fusion (Part 2) (Figure [S1](#cas14265-sup-0001){ref-type="supplementary-material"}). The current report describes results from Part 1; Part 2 of the study is ongoing and results will be described in a subsequent publication.

A mTPI design[18](#cas14265-bib-0018){ref-type="ref"} was used to determine the MTD of E7090, with each cohort assigned a dose of E7090 in accordance with the rules of the mTPI design based on a target DLT rate of 25% ± 5% (Table [S1](#cas14265-sup-0003){ref-type="supplementary-material"}). E7090 was given orally on a QD continuous schedule in 28‐day cycles. In cycle 0, patients received a single oral dose of E7090 (1 mg; the starting dose was determined based on preclinical animal toxicity studies) on day 1, followed by a washout period (days 2‐7) for PK analysis. Cycle 1 started between day 8 and day 10. For cycle 1 and subsequent cycles, the cycle length was 28 days and patients received E7090 QD until any of the predefined discontinuation criteria were met. If no patients experienced DLT at the starting dose, dose escalation was permitted, as summarized in Figure [S2](#cas14265-sup-0002){ref-type="supplementary-material"}.

This study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (Guideline for Good Clinical Practice), and was approved by the institutional review board at the study center. All patients provided written informed consent prior to participation. This study was registered in the Japan Pharmaceutical Information Center Clinical Trials Information registry (JapicCTI‐142740) and in ClinicalTrials.gov (NCT02275910).

2.3. Safety and tolerability {#cas14265-sec-0005}
----------------------------

Dose‐limiting toxicities (monitored during cycle 0‐cycle 1) were defined as any of the following AE: grade 4 neutropenia persisting for more than 7 days or febrile neutropenia; grade 4 thrombocytopenia or grade 3 thrombocytopenia requiring blood transfusion; any ≥grade 3 non‐hematological toxicity with the exception of abnormal clinical laboratory values with no clinical significance and any events that could be managed and controlled to ≤grade 2 by maximal medical management; new ectopic de novo calcification with clinical significance confirmed by radiological images; hyperphosphatemia defined as serum phosphate \>7 mg/dL persisting for \>7 days despite giving phosphate‐lowering therapy or \>9 mg/dL (single measurement) despite giving phosphate‐lowering therapy; and development of any toxicity considered to be related to E7090 and requiring treatment interruption for ≥8 days from cycle 0 to cycle 1. Phosphate binders were given when serum phosphate levels exceeded the institutional normal levels. During the DLT assessment period, concomitant therapies comprising any treatment, change in dosage, or changes in medication for the purpose of preventing the occurrence of a DLT were not permitted.

Adverse events were coded using the Medical Dictionary for Regulatory Activities v20.1, and severity grades were determined using the Common Terminology Criteria for Adverse Events v4.03.

2.4. Efficacy {#cas14265-sec-0006}
-------------

Tumor assessment by computed tomography and/or magnetic resonance imaging was carried out according to RECIST v1.1 guidelines[19](#cas14265-bib-0019){ref-type="ref"} at screening, once every 8 weeks from day 1 of cycle 1, and at study discontinuation.

2.5. Pharmacokinetic analysis {#cas14265-sec-0007}
-----------------------------

Blood samples for PK analysis were obtained before dosing in all cycles and at specific time points after giving E7090 up to cycle 3. Plasma and urine concentrations of E7090 were measured by LC‐MS/MS. To isolate E7090 from plasma, 10 µL IS and 500 µL of 5 mmol/L ammonium hydrogen carbonate were added to 100 µL plasma and vortexed. Solid‐phase extraction was carried out with an Oasis HLB µElution plate (Waters Corporation). After conditioning with 700 µL methanol and equilibration with 700 µL of 5 mmol/L ammonium hydrogen carbonate, samples were loaded onto the plate and washed with distilled water/methanol (3/2, v/v, 100 µL) and eluted with methanol/formic acid (100/1, v/v, 50 µL). The elution process was repeated twice and the eluate was subjected to LC‐MS/MS analysis under the following conditions. Reversed‐phase chromatography was run on an L‐column2 ODS (2.1 mm internal diameter × 150 mm, 3 μm, Chemicals Evaluation and Research Institute) at 40°C using a mobile phase consisting of distilled water (A) and acetonitrile/distilled water (4/1, v/v) (B) containing 15 mmol/L ammonium hydrogen carbonate (A:B = 40:60) at a flow rate of 0.25 mL/minute. E7090 and IS were detected by MS/MS using multiple reaction monitoring under the positive ionization mode.

2.6. Pharmacodynamics, pharmacogenomics and biomarker assessments {#cas14265-sec-0008}
-----------------------------------------------------------------

Blood samples, stored tumor samples, and tumor biopsy samples were obtained before giving E7090 in cycle 0, cycle 1, subsequent odd‐numbered cycles, and after dosing in cycle 0 for days 1‐4. Markers of FGFR pathway inhibition included serum phosphate, FGF23, and 1,25‐(OH)~2~‐vitamin D. FGF23 was detected by solid‐phase sandwich ELISA (FGF‐23 ELISA Kit; Kainos) using mouse anti‐human FGF23 and peroxidase‐conjugated mouse anti‐human FGF23 monoclonal antibodies, and colorimetric detection. Measurement of 1,25‐(OH)~2~‐vitamin D was done using a double‐antibody RIA. Sheep anti‐1,25‐(OH)~2~‐vitamin D antibody was added to pretreated samples, incubated for 16‐18 hours, and an ^125^I‐labeled 1,25‐(OH)~2~‐vitamin D tracer was added, followed by a cellulose‐conjugated donkey anti‐sheep IgG antibody. After removal of unbound tracer, radioactivity was measured (ARC‐950/ARC‐8010 γ‐counter \[Hitachi Ltd\], 1460SRL \[PerkinElmer Co., Ltd\]).

2.7. Statistical analyses {#cas14265-sec-0009}
-------------------------

Descriptive statistics were used to analyze demographic and other baseline characteristics and safety assessments. All patients who received at least one dose of E7090 were included in the safety analysis. These patients had one or more target lesions as defined by RECIST v1.1 and were included in the analysis of best overall response. Efficacy analysis set included patients in the safety analysis set who underwent tumor assessment at baseline and at least once post‐baseline. Plasma concentrations of E7090 were analyzed using a non‐compartmental analysis to determine PK parameters (maximum plasma concentration \[*C* ~max~\], time to reach maximum concentration \[*T* ~max~\], area under the concentration‐time curve \[AUC\], and clearance).

The number of patients required for inclusion in Part 1 of the study was estimated to be approximately 20, based on the recommended sample size to reach MTD using nine dose levels, each with a cohort size of two.

3. RESULTS {#cas14265-sec-0010}
==========

3.1. Patients {#cas14265-sec-0011}
-------------

A total of 24 patients (11 males, 13 females) were enrolled in the study between 10 November 2014 and 21 February 2017. Baseline characteristics are summarized in Table [1](#cas14265-tbl-0001){ref-type="table"}. Eight patients (33%) had cholangiocarcinoma and there were three cases (13%) of pancreatic cancer, two cases (8%) of endometrial cancer, two cases (8%) of cancer of unknown primary, and nine (38%) patients with other solid tumors. All 24 patients had measurable disease by RECIST criteria at baseline and had received prior chemotherapy, with nine (38%) having received two or fewer lines and 15 (63%) three or more lines of chemotherapy. No assessment of FGFR status (mutation, amplification, or fusion) was carried out during Part 1 of the study, although if available, information on FGFR status was collected from patients who had obtained such data from other examinations outside the present clinical trial.

###### 

Patient demographic and baseline characteristics

                                                            All patients N = 24 (%)
  ------------------------------------ -------------------- -------------------------
  Age, years                           Median (range)       65 (42‐75)
  Gender                               Male                 11 (45.8)
  Female                               13 (54.2)            
  ECOG‐PS                              0                    17 (70.8)
  1                                    7 (29.2)             
  No. of prior lines of chemotherapy   ≤2                   9 (37.5)
  ≥3                                   15 (62.5)            
  Cancer type                          Cholangiocarcinoma   8 (33.3)
  Pancreatic cancer                    3 (12.5)             
  Endometrial cancer                   2 (8.3)              
  Cancer of unknown primary            2 (8.3)              
  Other                                9 (37.5)             

Abbreviation: PS, performance status.

John Wiley & Sons, Ltd

3.2. Safety {#cas14265-sec-0012}
-----------

No DLT was observed between 1 mg QD and 140 mg QD. Of the 24 patients treated, three experienced a SAE (dyspnea in one subject in the 8‐mg QD cohort, tumor pain in one subject in the 8‐mg QD cohort, and pyrexia in one subject in the 30‐mg cohort). None of the SAE was considered to be related to the study drug (Table [2](#cas14265-tbl-0002){ref-type="table"}).

###### 

Treatment‐related treatment‐emergent adverse events (occurring in ≥10% of the total study population)

  Preferred term[a](#cas14265-note-0006){ref-type="fn"}   1‐30 mg (n = 12)   60 mg (n = 3)   100 mg (n = 3)   140 mg (n = 3)   180 mg (n = 3)   Total (N = 24)                                                      
  ------------------------------------------------------- ------------------ --------------- ---------------- ---------------- ---------------- ---------------- ----------- ---- ----------- ---------- ---------- ---------
  Blood creatinine increased                              2 (16.7)           --              2 (66.7)         --               1 (33.3)         --               3 (100.0)   --   1 (33.3)    --         9 (37.5)   --
  Hyperphosphatemia                                       --                 --              --               --               3 (100.0)        --               3 (100.0)   --   3 (100.0)   --         9 (37.5)   --
  ALT increased                                           --                 --              1 (33.3)         --               --               --               3 (100.0)   --   2 (66.7)    2 (66.7)   6 (25.0)   2 (8.3)
  Diarrhea                                                --                 --              2 (66.7)         --               --               --               1 (33.3)    --   3 (100.0)   --         6 (25.0)   --
  Lipase increased                                        1 (8.3)            --              1 (33.3)         --               1 (33.3)         --               1 (33.3)    --   1 (33.3)    --         5 (20.8)   --
  Nausea                                                  1 (8.3)            --              1 (33.3)         --               1 (33.3)         --               1 (33.3)    --   1 (33.3)    --         5 (20.8)   --
  AST increased                                           --                 --              --               --               --               --               2 (66.7)    --   2 (66.7)    1 (33.3)   4 (16.7)   1 (4.2)
  PPE syndrome                                            --                 --              1 (33.3)         --               --               --               1 (33.3)    --   2 (66.7)    --         4 (16.7)   --
  Anemia                                                  --                 --              1 (33.3)         --               1 (33.3)         --               1 (33.3)    --   --          --         3 (12.5)   --
  Blood ALP increased                                     --                 --              --               --               1 (33.3)         --               2 (66.7)    --   --          --         3 (12.5)   --
  Dysgeusia                                               --                 --              --               --               --               --               2 (66.7)    --   1 (33.3)    --         3 (12.5)   --
  Retinal detachment                                      --                 --              --               --               2 (66.7)         --               1 (33.3)    --   --          --         3 (12.5)   --
  Vomiting                                                --                 --              1 (33.3)         --               --               --               1 (33.3)    --   1 (33.3)    1 (33.3)   3 (12.5)   1 (4.2)

Values are shown as n (%); percentages are based on the number of treated patients in the relevant treatment cohort.

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PPE, palmar‐plantar erythrodysesthesia; --, no incidence.

Coded using the Medical Dictionary for Regulatory Activities, version 20.1.

John Wiley & Sons, Ltd

No drug‐related deaths were reported, and no TEAE led to discontinuation of the study drug. TEAE leading to dose reductions were increased ALT (n = 2), increased AST (n = 1), and PPE syndrome (n = 2). Reasons for TEAE‐related dose interruptions included nausea (n = 3), vomiting (n = 2), anorexia (n = 2), nasopharyngitis (n = 1), and decreased neutrophil count (n = 1). Selective FGFR inhibition has been associated with an increased risk of hyperphosphatemia[20](#cas14265-bib-0020){ref-type="ref"} and eye toxicity, including retinal detachment.[8](#cas14265-bib-0008){ref-type="ref"}, [13](#cas14265-bib-0013){ref-type="ref"} In the present study, there were nine AE of hyperphosphatemia and three AE of retinal detachment, but all were \<grade 3 in severity and did not lead to dose reduction or discontinuation.

The dose levels are shown in Figure [S2](#cas14265-sup-0002){ref-type="supplementary-material"}. One patient experienced a DLT (grade 3 increased AST/ALT) in the 180‐mg cohort, whereas no DLT were reported at doses up to and including 140 mg. Because sufficient inhibition of the targeted signaling pathway was obtained at 100‐140 mg (as shown by PD markers described in the later section) and the safety profile at this dose level was acceptable, the recommended dose for Part 2 was determined as 140 mg QD.

3.3. Pharmacokinetics {#cas14265-sec-0013}
---------------------

Following both single and repeat oral administration, once‐daily E7090 was cleared from plasma with a mean terminal elimination phase half‐life (*T* ~1/2~) of 15‐27 hours. Dose‐dependent increases in *C* ~max~ and AUC~(0‐~ *~t~* ~)~ were observed up to 180 mg E7090 (Figure [1](#cas14265-fig-0001){ref-type="fig"}). *T* ~max~ was similar among doses, with a median of 2‐5 hours. Excretion of unchanged form into urine was low (data not shown). The PK parameters are presented in Table [3](#cas14265-tbl-0003){ref-type="table"} and include data only from patients who received ≥30 mg E7090, as plasma concentrations in the 1‐16‐mg cohorts at 72 hours after dosing were below the limit of quantification.

![Relationship between E7090 dose and pharmacokinetic parameters. A, Maximum plasma concentration (*C* ~max~). B, AUC~(0‐t)~ (single‐dose study). AUC, area under the concentration‐time curve](CAS-111-571-g001){#cas14265-fig-0001}

###### 

Pharmacokinetic parameters of E7090

                             30 mg (n = 2)   60 mg (n = 3)                                    100 mg (n = 3)   140 mg (n = 3)   180 mg (n = 3)
  -------------------------- --------------- ------------------------------------------------ ---------------- ---------------- ----------------
  Single                                                                                                                        
  *T* ~1/2~ (h)              23              23 ± 8                                           15 ± 2           27 ± 12          24 ± 10
  *T* ~max~ (h)              3 (1‐5)         3 (3‐5)                                          5 (3‐5)          5 (3‐5)          2 (2‐5)
  *C* ~max~ (ng/mL)          28              39 ± 5                                           86 ± 31          227 ± 118        154 ± 38
  AUC~(0‐t)~ (h × ng/mL)     222             533 ± 257                                        1080 ± 474       3960 ± 3230      2570 ± 933
  AUC~(0‐inf)~ (h × ng/mL)   239             554 ± 247                                        1120 ± 479       4050 ± 3340      2610 ± 921
  Vz/F (L)                   4180            3790 ± 1240                                      2310 ± 1360      1670 ± 617       2550 ± 1550
  CL/F (L/h)                 127             121 ± 43                                         103 ± 48         59 ± 50          74 ± 22
  Repeated                                                                                                                      
  *T* ~max~ (h)              4 (3‐5)         3 (2‐3)[a](#cas14265-note-0009){ref-type="fn"}   3 (2‐5)          5 (3‐5)          5 (3‐5)
  *C* ~max~ (ng/mL)          13              51[a](#cas14265-note-0009){ref-type="fn"}        116 ± 4          372 ± 173        337 ± 60
  AUC~(0‐t)~ (h × ng/mL)     162             507[a](#cas14265-note-0009){ref-type="fn"}       1340 ± 437       4700 ± 3380      3860 ± 764
  *C* ~min~ (ng/mL)          5               11[a](#cas14265-note-0009){ref-type="fn"}        22 ± 9           117 ± 116        65 ± 19
  *C* ~avg~ (ng/mL)          7               21[a](#cas14265-note-0009){ref-type="fn"}        56 ± 18          196 ± 141        161 ± 32

Data are shown as mean ± SD, except *T* ~max~; for *T* ~max~, median (range) is shown.

Abbreviations: AUC, area under the concentration‐time curve; *C* ~avg~, average plasma concentration; CL/F, total clearance; *C* ~max~, maximum plasma concentration; *C* ~min~, minimum plasma concentration;*T* ~1/2~, terminal elimination phase half‐life; *T* ~max~, time to reach maximum plasma concentration; Vz/F, volume of distribution.

n = 2; data are missing for one patient who discontinued treatment prior to cycle 1, day 22 because of progressive disease.

John Wiley & Sons, Ltd

3.4. Pharmacodynamics {#cas14265-sec-0014}
---------------------

E7090 administration induced dose‐dependent increases in serum phosphate, FGF23, and 1,25‐(OH)~2~‐vitamin D, and these increases reached a maximum at approximately 100‐140 mg QD. Percent changes from baseline of PD markers of FGFR pathway inhibition (cycle 1, day 15) are shown in Figure [2](#cas14265-fig-0002){ref-type="fig"}.

![Percent change from baseline of pharmacodynamic markers of fibroblast growth factor receptor (FGFR) pathway inhibition. A, Serum phosphate. B, Fibroblast growth factor 23 (FGF23). C, 1,25‐(OH)~2~‐vitamin D (cycle 1 day 15)](CAS-111-571-g002){#cas14265-fig-0002}

3.5. Antitumor activity {#cas14265-sec-0015}
-----------------------

One patient achieved a partial response and seven patients achieved stable disease (Table [S2](#cas14265-sup-0004){ref-type="supplementary-material"}). Fourteen patients had a best overall response of progressive disease, and two patients were not evaluable. The patient (a 45‐year‐old woman) who showed a partial response was in the 180‐mg cohort, had diffuse‐type gastric cancer with para‐aortic lymph node and bone metastases (poorly differentiated adenocarcinoma) and FGFR2 amplification (copy number 51 by next‐generation sequencing), and had undergone three prior lines of chemotherapy. A 71% reduction in diameter of the target lesion (from 38 to 11 mm) was observed at cycle 3 day 1 (Figure [3](#cas14265-fig-0003){ref-type="fig"}). The patient discontinued treatment on cycle 4, day 8 because of progressive disease.

![Computed tomography images showing antitumor activity of E7090. A, Baseline. B, Cycle 3, day 1 in the patient who achieved a partial response. The target lesion (para‐aortic lymphadenopathy) was reduced by 71% (from 38 to 11 mm). Arrows show the target lesion](CAS-111-571-g003){#cas14265-fig-0003}

4. DISCUSSION {#cas14265-sec-0016}
=============

In the present study, E7090 was evaluated as monotherapy at total daily doses ranging from 1 to 180 mg in 24 patients with advanced solid tumors. Based on the study findings, E7090 appears to have a tolerable and manageable safety profile, with tumor/FGFR gene alteration‐specific efficacy.

Pharmacokinetic data indicated rapid absorption of E7090; exposure as measured by *C* ~max~ and AUC~(0‐t)~ increased with dose escalation. Dose‐dependent increases in PD markers of FGFR pathway inhibition[17](#cas14265-bib-0017){ref-type="ref"} were observed for serum phosphate, FGF23, and 1,25‐(OH)~2~‐vitamin D and reached a plateau at 100‐140 mg, indicating that doses ≥100 mg QD sufficiently inhibited the FGFR pathway. PD data from previous phase I studies in other specific FGFR inhibitors have been inconclusive. For example, treatment with JNJ‐42756493 was associated with increased phosphate and 1,25‐(OH)~2~‐vitamin D but not FGF23 in studies in solid tumors,[11](#cas14265-bib-0011){ref-type="ref"}, [21](#cas14265-bib-0021){ref-type="ref"} whereas AZD4547 has also been shown to increase serum phosphate but not FGF23.[7](#cas14265-bib-0007){ref-type="ref"}

The toxicity profile of E7090 was generally consistent with previous findings in non‐clinical studies. In the present study, SAE occurred in three patients (although none was considered related to the study drug), and no drug‐related deaths or TEAE requiring discontinuation of the study drug were reported. For Part 2, 140 mg QD was selected as the recommended dose based on the dose‐dependent increases in PK parameters and in serum phosphate, FGF23, and 1,25‐(OH)~2~‐vitamin D observed following E7090 administration, which reached a maximum at approximately 100‐140 mg QD; and the absence of any AE ≥grade 3 observed at this dose. The dosage schedule (once‐daily continuous dosing) for Part 2 was also considered to be appropriate, based on the elimination half‐life of the drug; for safety reasons, intermittent dosing was not considered a suitable regimen for E7090. Although MTD was not reached, E7090 is a molecular targeted agent and sufficient inhibition of the targeted signaling pathway was achieved between 100‐140 mg QD. In the context of selecting an appropriate dose for Part 2, determination of MTD is therefore not essential. FGFR signaling is involved in the regulation of FGF23 expression,[17](#cas14265-bib-0017){ref-type="ref"} and increased FGF23 production has been implicated in the development of several hypophosphatemic diseases.[22](#cas14265-bib-0022){ref-type="ref"}, [23](#cas14265-bib-0023){ref-type="ref"}, [24](#cas14265-bib-0024){ref-type="ref"} Selective FGFR inhibitors are typically associated with on‐target toxicities such as hyperphosphatemia, which appears to play a role in FGF23 signaling[20](#cas14265-bib-0020){ref-type="ref"} and eye toxicity such as macular edema and retinal detachment, as reported previously.[8](#cas14265-bib-0008){ref-type="ref"}, [13](#cas14265-bib-0013){ref-type="ref"} No clear relationship between these toxicities and the inhibition of FGFR has been found. Skin and eye toxicities are a concern as a class effect of FGFR inhibition[1](#cas14265-bib-0001){ref-type="ref"} and although PPE syndrome and retinal detachment AE occurred in this study, they were \<grade 3, manageable, and did not lead to dose discontinuation. Similarly, in a phase I study of JNJ‐42756493, detachment of retinal pigment epithelium \<grade 3 was the only DLT observed, and occurred only at the highest dose investigated (12 mg).[21](#cas14265-bib-0021){ref-type="ref"} However, in a phase I study of AZD4547, grade 3 central serous retinopathy was reported in two patients in a dose‐escalation cohort.[7](#cas14265-bib-0007){ref-type="ref"}

With respect to efficacy, promising antitumor activity was observed in one gastric cancer patient with an FGFR2 amplification. Although E7090 did not show potent antitumor activity in patients with cholangiocarcinoma with FGFR2 fusion in the 30‐mg cohort, this could be attributable to insufficient dosing. In preclinical models of tumors harboring FGFR abnormalities, E7090 elicited a significantly prolonged survival effect in mice with tumors metastasized to the lung.[16](#cas14265-bib-0016){ref-type="ref"} In a previous study of AZD4547, a selective FGFR1‐3 inhibitor, in patients with advanced gastric cancer showing FGFR2 polysomy or gene amplification, no significant effect on progression‐free survival was observed by AZD4547 compared with paclitaxel, although considerable intratumor heterogeneity was observed in the study population.[25](#cas14265-bib-0025){ref-type="ref"} However, phase II data on the efficacy of JNJ‐42756493 in patients with advanced urothelial cancer showing specific FGFR genetic alterations indicated promising outcomes, including a 32% objective response rate and median response duration of 5.4 months.[10](#cas14265-bib-0010){ref-type="ref"}

A limitation of this first‐in‐human study was the small number of patients included, an inherent feature of early‐phase trials. A notable feature of the present study was the use of a modified toxicity probability interval design, which has been shown to be a safer and more robust alternative to the standard 3 + 3 design for phase I dose‐escalation oncology trials.[18](#cas14265-bib-0018){ref-type="ref"}

In conclusion, this first‐in‐human phase I study indicates that E7090 has an acceptable safety profile; dose‐dependent PK parameters; and the potential for clinical efficacy in FGFR2‐amplified gastric cancer. Further evaluation (in Part 2) of patients with FGFR2‐amplified gastric cancer and FGFR2‐fusion‐positive cholangiocarcinoma is ongoing. It is becoming increasingly apparent that FGFR aberrations vary according to tumor histology, meaning that a more detailed understanding of the role of FGF/FGFR in cancer is required.
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